Trim43B: A novel protein target for drug development and cancer diagnosis

Target Name: TRIM43B

NCBI ID: G653192

TRIM43B

Trim43B: A novel protein target for drug development and cancer diagnosis

Abstract:

Trim43B, also known as Tripartite motif-containing protein 43B, is a gene that encodes a protein with unique structural features. It has been shown to play a crucial role in various cellular processes, including cell signaling, DNA replication, and stress responses. The identification of Trim43B as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases, including cancer.

Introduction:

The protein Trim43B, also known as Tripartite motif-containing protein 43B, is a gene that encodes a protein with unique structural features. It has been shown to play a crucial role in various cellular processes, including cell signaling, DNA replication, and stress responses. The identification of Trim43B as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases, including cancer.

Structure and function:

Trim43B is a 21 kDa protein that contains three distinct domains: an N-terminal domain, a middle domain, and an C-terminal domain. The N-terminal domain contains a putative transmembrane domain and a short cytoplasmic domain. The middle domain contains a unique 尾-sheet structure that is composed of three parallel 尾-strands, each of which is held together by a disulfide bond. The C-terminal domain contains a C-type zinc finger and a short amino acid tail.

Trim43B is a key regulator of various cellular processes, including cell signaling, DNA replication, and stress responses. It has been shown to play a critical role in the regulation of cell proliferation and survival. For example, Trim43B has been shown to be involved in the regulation of the G1/S transition, which is a critical step in the cell cycle that leads to the entry of the cell into the G2 phase.

In addition to its role in cell signaling, Trim43B has also been shown to play a crucial role in the regulation of DNA replication. It has been shown to interact with the enzyme responsible for DNA replication, called DNA polymerase II (DNA-PSI), and to regulate the activity of DNA-PSI. This interaction between Trim43B and DNA-PSI suggests that Trim43B may be a potential drug target for diseases that are characterized by disruptions in DNA replication, such as cancer.

Trim43B has also been shown to play a role in stress responses. It has been shown to interact with the protein known as p21, which is a well-known stress-responsive protein that is involved in the regulation of cell growth and apoptosis. This interaction between Trim43B and p21 suggests that Trim43B may be a potential drug target for diseases that are characterized by disruptions in stress responses, such as neurodegenerative diseases.

Drug targeting:

The identification of Trim43B as a potential drug target has significant implications for the development of new treatments for various diseases. One approach to targeting Trim43B is to use small molecules that can modulate its activity. This approach is based on the idea that by modulating the activity of Trim43B, it is possible to inhibit its function as a drug target and prevent the development of diseases associated with Trim43B dysfunction.

Compound libraries have been generated to identify small molecules that can modulate the activity of Trim43B. Many of these compounds have been shown to be effective in inhibiting the activity of Trim43B and have been tested in animal models of disease. For example, a compound called Y101 has been shown to be an effective inhibitor of Trim43B

Protein Name: Tripartite Motif Containing 43B

The "TRIM43B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM43B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets